This announcement serves to conclude drug discount agreements in accordance with § 130c para. 1 SGB V concerning the active substance (s) referred to in point II.1.1). It is not public procurement within the meaning of Directive 2014/24/EU or Sections 97 et seq. GWB. Any pharmaceutical entrepreneur can become a contractual partner in accordance with § 4 paragraph 18 AMG. According to the case law of the ECJ, such admission procedures are not necessarily subject to procurement law, as no competition takes place due to the lack of selection decision. The announcement serves as an invitation to conclude discount contracts with the same and non-dispositive conditions applicable to all contracting partners, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point designated under I.3).

The earliest start date of the contract is 01.05.2023 if the signed contract and the required declarations have been received by 04.04.2023 at the contact point named under I.3). This is referred to in IV.2.2). In the event of later receipt, the contract shall commence on the 1st of the month following the month of receipt of the signed contract and the required declarations or evidence at the contact point named under I.3), provided that the receipt is made by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contracts are concluded for the active substance(s) or combination of active substances under a procurement procedure. The contracts end on 30.04.2025.